Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hackensack Meridian Health
Massachusetts General Hospital
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
University of Chicago
University of Washington
Institute of Hematology & Blood Diseases Hospital, China
Sunnybrook Health Sciences Centre
Eli Lilly and Company